Phase 2 N=40 Calcium Chloride for Prevention of Uterine Atony During Cesarean
Uterine Atony · Uterine Atony With Hemorrhage · Cesarean Section Complications
Primary: Uterine Atony — 4; 10 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=14 Sleep and Breathing in the General Population - Chemical Stimuli
Sleep-disordered Breathing
Primary: The Central Apnea-hypopnea Index — 14.1; 29.9 events per hour
Phase 3 N=15 Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals
HIV-1-infection
Primary: Total Doravirine Concentrations in Cerebrospinal Fluid — 58.6 ng/ml
Phase 1 N=51 Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine
Mosquito-Borne Infectious Diseases
Primary: Incidence of Severity of Treatment Emergent Adverse Events (AEs) by Grade — 7; 8; 10; 8 Participants
Phase 3 N=364 Mirena Extension Trial
Contraception
Primary: Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use — 0.28 Pregnancies per 100 women years
N/A N=15 A Device to Determine Return of Sensation From Spinal Block
Sensation Diminished, Pinprick
Primary: Block Recovery Time (Device) — 40.7 minutes
Phase 2 N=32 Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
Breast Cancer
Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants
N/A N=115 Effects of Cardiac Rehabilitation (CR) on Functional Capacity and Cardiovascular Risk Factors
Cardiovascular Disease · Coronary Disease
Primary: Functional Capacity Assessed by Changes in Total Distance Walked in the Incremental Shuttle Walk Test — 488.1; 464.8; 394.0 meters
Phase 3 N=3 A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia
Aplastic Anemia
Primary: Number of Participants With Hematologic Response at Week 12 — 2; 1 Participants
Phase 3 N=114 Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up
Opioid-use Disorder · Hiv
Primary: Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed — 23; 21; 29; 29 Participants
Phase 2 N=19 Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage III Prostate Cancer
Primary: Metabolic Syndrome Incidence, Summarized by the Number of Patients With at Least 3 of the 5 Pre-specified Criteria — 5; 3 Participants — p=0.46
Phase 4 N=50 Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients
Cardiovascular Risk Factor
Primary: LDL-C at Month 3 — 145 mg/dL — p=0.03
Phase 2 N=17 Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
B-cell Malignancies
Primary: Part 1 and Part 2: Number of Participants With Adverse Events — 3; 4; 5; 274 Participants
Phase 2 N=70 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Primary: Objective Response Rate (ORR)
Phase 2 N=123 Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 24 — 93.1; 100.0; 90.3; 90.3 Percentage of participants